MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 26.4% in April

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 42,300 shares, a decline of 26.4% from the March 31st total of 57,500 shares. Based on an average daily volume of 670,400 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the company’s stock are short sold.

Institutional Trading of MIRA Pharmaceuticals

An institutional investor recently bought a new position in MIRA Pharmaceuticals stock. Praetorian Wealth Management Inc. purchased a new position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 27,500 shares of the company’s stock, valued at approximately $30,000. Praetorian Wealth Management Inc. owned approximately 0.19% of MIRA Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 35.16% of the stock is currently owned by hedge funds and other institutional investors.

MIRA Pharmaceuticals Stock Performance

NASDAQ:MIRA opened at $0.86 on Friday. The company’s 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.59. MIRA Pharmaceuticals has a fifty-two week low of $0.76 and a fifty-two week high of $7.98.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its earnings results on Monday, April 1st. The company reported ($0.19) earnings per share for the quarter. On average, sell-side analysts predict that MIRA Pharmaceuticals will post -0.39 earnings per share for the current fiscal year.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.